Triaryimethanes, a new class of Cx50 inhibitors

Silke B. Bodendiek, Clio Rubinos, Maria Pilar Trelles, Nichole Coleman, David Paul Jenkins, Heike Wulff, Midutur Srinivas

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The paucity of specific pharmacological agents has been a major impediment for delineating the roles of gap junction (GJ) channels formed by connexin proteins in physiology and pathophysiology. Here, we used the selective optimization of side activities (SOSA) approach, which has led to the design of high affinity inhibitors of other ion channels, to identify a specific inhibitor for channels formed by Cx50, a connexin subtype that is primarily expressed in the lens. We initially screened a library of common ion channel modulating pharmacophores for their inhibitory effects on Cx50 GJ channels, and identified four new classes of compounds. The triarlymethane (TRAM) clotrimazole was the most potent Cx50 inhibitor and we therefore used it as a template to explore the structure activity relationship (SAR) of the TRAMs for Cx50 inhibition. We describe the design ofT122 (A/-[(2-methoxyphenyl)diphenylmethyl]-1,3-thiazol-2-amine) andT136 (A/-[(2-iodophenyl)diphenylmethyl]-1,3-thiazol-2-amine), which inhibit Cx50 with IC50s of 1.2 and 2.4 μM. Both compounds exhibit at least 10-fold selectivity over other connexins as well as major neuronal and cardiac voltage-gated K+ and Na+ channels. The SAR studies also indicated that theTRAM pharmacophore required for connexin inhibition is significantly different from thepharmacophore required for blocking the calcium-activated KCa3.1 channel. BothT122 andT136 selectively inhibited Cx50 GJ channels in lens epithelial cells, suggesting that they could be used to further explore the role of Cx50 in the lens. In addition, our results indicate that a similar approach may be used to find specific inhibitors of other connexin subtypes.

Original languageEnglish (US)
Article number106
JournalFrontiers in Pharmacology
Volume3 JUN
DOIs
StatePublished - 2012

Fingerprint

Connexins
Gap Junctions
Lenses
Structure-Activity Relationship
Ion Channels
Amines
Clotrimazole
Voltage-Gated Potassium Channels
Epithelial Cells
Pharmacology
Calcium
Proteins

Keywords

  • Channel
  • Connexin 50
  • Gap junctions
  • Inhibitors
  • Lens
  • Pharmacophore
  • SAR
  • Triarylmethane

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Bodendiek, S. B., Rubinos, C., Trelles, M. P., Coleman, N., Jenkins, D. P., Wulff, H., & Srinivas, M. (2012). Triaryimethanes, a new class of Cx50 inhibitors. Frontiers in Pharmacology, 3 JUN, [106]. https://doi.org/10.3389/fphar.2012.00106

Triaryimethanes, a new class of Cx50 inhibitors. / Bodendiek, Silke B.; Rubinos, Clio; Trelles, Maria Pilar; Coleman, Nichole; Jenkins, David Paul; Wulff, Heike; Srinivas, Midutur.

In: Frontiers in Pharmacology, Vol. 3 JUN, 106, 2012.

Research output: Contribution to journalArticle

Bodendiek, SB, Rubinos, C, Trelles, MP, Coleman, N, Jenkins, DP, Wulff, H & Srinivas, M 2012, 'Triaryimethanes, a new class of Cx50 inhibitors', Frontiers in Pharmacology, vol. 3 JUN, 106. https://doi.org/10.3389/fphar.2012.00106
Bodendiek SB, Rubinos C, Trelles MP, Coleman N, Jenkins DP, Wulff H et al. Triaryimethanes, a new class of Cx50 inhibitors. Frontiers in Pharmacology. 2012;3 JUN. 106. https://doi.org/10.3389/fphar.2012.00106
Bodendiek, Silke B. ; Rubinos, Clio ; Trelles, Maria Pilar ; Coleman, Nichole ; Jenkins, David Paul ; Wulff, Heike ; Srinivas, Midutur. / Triaryimethanes, a new class of Cx50 inhibitors. In: Frontiers in Pharmacology. 2012 ; Vol. 3 JUN.
@article{4633fe2ff6da4e86823ca7fff90776dd,
title = "Triaryimethanes, a new class of Cx50 inhibitors",
abstract = "The paucity of specific pharmacological agents has been a major impediment for delineating the roles of gap junction (GJ) channels formed by connexin proteins in physiology and pathophysiology. Here, we used the selective optimization of side activities (SOSA) approach, which has led to the design of high affinity inhibitors of other ion channels, to identify a specific inhibitor for channels formed by Cx50, a connexin subtype that is primarily expressed in the lens. We initially screened a library of common ion channel modulating pharmacophores for their inhibitory effects on Cx50 GJ channels, and identified four new classes of compounds. The triarlymethane (TRAM) clotrimazole was the most potent Cx50 inhibitor and we therefore used it as a template to explore the structure activity relationship (SAR) of the TRAMs for Cx50 inhibition. We describe the design ofT122 (A/-[(2-methoxyphenyl)diphenylmethyl]-1,3-thiazol-2-amine) andT136 (A/-[(2-iodophenyl)diphenylmethyl]-1,3-thiazol-2-amine), which inhibit Cx50 with IC50s of 1.2 and 2.4 μM. Both compounds exhibit at least 10-fold selectivity over other connexins as well as major neuronal and cardiac voltage-gated K+ and Na+ channels. The SAR studies also indicated that theTRAM pharmacophore required for connexin inhibition is significantly different from thepharmacophore required for blocking the calcium-activated KCa3.1 channel. BothT122 andT136 selectively inhibited Cx50 GJ channels in lens epithelial cells, suggesting that they could be used to further explore the role of Cx50 in the lens. In addition, our results indicate that a similar approach may be used to find specific inhibitors of other connexin subtypes.",
keywords = "Channel, Connexin 50, Gap junctions, Inhibitors, Lens, Pharmacophore, SAR, Triarylmethane",
author = "Bodendiek, {Silke B.} and Clio Rubinos and Trelles, {Maria Pilar} and Nichole Coleman and Jenkins, {David Paul} and Heike Wulff and Midutur Srinivas",
year = "2012",
doi = "10.3389/fphar.2012.00106",
language = "English (US)",
volume = "3 JUN",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Triaryimethanes, a new class of Cx50 inhibitors

AU - Bodendiek, Silke B.

AU - Rubinos, Clio

AU - Trelles, Maria Pilar

AU - Coleman, Nichole

AU - Jenkins, David Paul

AU - Wulff, Heike

AU - Srinivas, Midutur

PY - 2012

Y1 - 2012

N2 - The paucity of specific pharmacological agents has been a major impediment for delineating the roles of gap junction (GJ) channels formed by connexin proteins in physiology and pathophysiology. Here, we used the selective optimization of side activities (SOSA) approach, which has led to the design of high affinity inhibitors of other ion channels, to identify a specific inhibitor for channels formed by Cx50, a connexin subtype that is primarily expressed in the lens. We initially screened a library of common ion channel modulating pharmacophores for their inhibitory effects on Cx50 GJ channels, and identified four new classes of compounds. The triarlymethane (TRAM) clotrimazole was the most potent Cx50 inhibitor and we therefore used it as a template to explore the structure activity relationship (SAR) of the TRAMs for Cx50 inhibition. We describe the design ofT122 (A/-[(2-methoxyphenyl)diphenylmethyl]-1,3-thiazol-2-amine) andT136 (A/-[(2-iodophenyl)diphenylmethyl]-1,3-thiazol-2-amine), which inhibit Cx50 with IC50s of 1.2 and 2.4 μM. Both compounds exhibit at least 10-fold selectivity over other connexins as well as major neuronal and cardiac voltage-gated K+ and Na+ channels. The SAR studies also indicated that theTRAM pharmacophore required for connexin inhibition is significantly different from thepharmacophore required for blocking the calcium-activated KCa3.1 channel. BothT122 andT136 selectively inhibited Cx50 GJ channels in lens epithelial cells, suggesting that they could be used to further explore the role of Cx50 in the lens. In addition, our results indicate that a similar approach may be used to find specific inhibitors of other connexin subtypes.

AB - The paucity of specific pharmacological agents has been a major impediment for delineating the roles of gap junction (GJ) channels formed by connexin proteins in physiology and pathophysiology. Here, we used the selective optimization of side activities (SOSA) approach, which has led to the design of high affinity inhibitors of other ion channels, to identify a specific inhibitor for channels formed by Cx50, a connexin subtype that is primarily expressed in the lens. We initially screened a library of common ion channel modulating pharmacophores for their inhibitory effects on Cx50 GJ channels, and identified four new classes of compounds. The triarlymethane (TRAM) clotrimazole was the most potent Cx50 inhibitor and we therefore used it as a template to explore the structure activity relationship (SAR) of the TRAMs for Cx50 inhibition. We describe the design ofT122 (A/-[(2-methoxyphenyl)diphenylmethyl]-1,3-thiazol-2-amine) andT136 (A/-[(2-iodophenyl)diphenylmethyl]-1,3-thiazol-2-amine), which inhibit Cx50 with IC50s of 1.2 and 2.4 μM. Both compounds exhibit at least 10-fold selectivity over other connexins as well as major neuronal and cardiac voltage-gated K+ and Na+ channels. The SAR studies also indicated that theTRAM pharmacophore required for connexin inhibition is significantly different from thepharmacophore required for blocking the calcium-activated KCa3.1 channel. BothT122 andT136 selectively inhibited Cx50 GJ channels in lens epithelial cells, suggesting that they could be used to further explore the role of Cx50 in the lens. In addition, our results indicate that a similar approach may be used to find specific inhibitors of other connexin subtypes.

KW - Channel

KW - Connexin 50

KW - Gap junctions

KW - Inhibitors

KW - Lens

KW - Pharmacophore

KW - SAR

KW - Triarylmethane

UR - http://www.scopus.com/inward/record.url?scp=84866165907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866165907&partnerID=8YFLogxK

U2 - 10.3389/fphar.2012.00106

DO - 10.3389/fphar.2012.00106

M3 - Article

VL - 3 JUN

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

M1 - 106

ER -